Tuesday brought an interesting mix of winners and losers as retail investors digested labor market data and parsed through some noteworthy corporate developments. The U.S. jobs picture continued to soften, with nonfarm payrolls rising just 64,000 in November—only slightly above expectations but historically weak—while the unemployment rate unexpectedly ticked up to 4.6%.
Against that backdrop, the major indexes had a mixed session. The Dow Jones Industrial Average slipped 0.6% to 48,114.26, and the S&P 500 dropped 0.2% to 6,800.26. The Nasdaq managed to eke out a 0.2% gain, closing at 23,111.46.
Here's a closer look at five stocks that captured the market's attention on Tuesday.
Tilray Brands: Cannabis Reclassification Hopes Send Shares Soaring
Tilray Brands Inc. (TLRY) absolutely ripped higher on Tuesday, jumping 27.54% to close at $13.94. The stock traded in a wide range between $10.50 and $14.55 during the session, and while shares remain well below their 52-week high of $23.20, they're comfortably above the 52-week low of $3.51.
What sparked the rally? The cannabis producer extended a multi-session surge as speculation intensified around potential U.S. marijuana reclassification. President Donald Trump recently said he is "very strongly" considering an executive order to move marijuana to Schedule III—a shift that would effectively reduce federal restrictions on the drug. Adding more fuel to the fire, Tilray CEO Irwin Simon made bullish remarks that aligned perfectly with the improving technical setup in the stock.
The combination of presidential commentary and executive optimism created a powerful catalyst for a sector that's been starved for positive regulatory news. When you get that kind of policy tailwind, traders tend to pile in quickly.
Pfizer: Cautious Outlook Weighs on Pharma Giant
Pfizer Inc. (PFE) had a rougher day, falling 3.48% to finish at $25.53. Shares bounced between $24.92 and $26.51 during trading, staying below their 52-week high of $27.69 but above the 52-week low of $20.92.
The pharmaceutical heavyweight stumbled after issuing a cautious longer-term outlook. The company's new 2026 forecast pointed to slower growth as COVID-19 revenues continue to fade and several key drugs face losses of exclusivity—patent cliffs that will allow generic competition. CEO Albert Bourla tried to balance the picture by highlighting cost-cutting initiatives and a focused R&D pipeline designed to support growth once those patent expirations pass, but investors seemed more concerned about the near-term headwinds.
It's a classic pharma problem: you make a ton of money on blockbuster drugs, then the patents expire, and suddenly you need the next generation of treatments to pick up the slack. Wall Street isn't convinced Pfizer's timeline lines up perfectly.
Netflix: Expanding Beyond Video with Podcast Partnership
Netflix Inc. (NFLX) gained 0.85% to close at $94.57, trading between $93.32 and $94.93 during the session. The streaming platform sits below its 52-week high of $134.12 but well above its 52-week low of $82.11.
The entertainment giant drew fresh interest after announcing a podcast partnership with iHeartMedia. It's an interesting strategic move that underscores Netflix's broader ambitions to expand its audio and content ecosystem beyond traditional video streaming. The company clearly wants to deepen user engagement across multiple formats, and podcasts represent a natural extension of its content strategy.
Think of it this way: Netflix already knows what you like to watch. Why not figure out what you like to listen to as well? More engagement means more reasons to keep that subscription active, and in the streaming wars, retention is everything.
Lennar: Homebuilder Beats Revenue But Misses Earnings
Lennar Corporation (LEN) slipped 1.80% during regular trading to settle at $117.57, having moved between $116.70 and $120.82 during the session. Shares remain below their 52-week high of $153.48 but above the 52-week low of $98.42. The pain intensified in after-hours trading, with the stock falling an additional 4.2% to $112.60.
The homebuilder reported fourth-quarter revenue of $9.37 billion, which beat analyst estimates, but adjusted earnings of $2.03 per share missed expectations. Home sales revenue fell 7% to $8.9 billion, reflecting the challenging environment for housing. On a more positive note, new orders rose 18% year over year to 20,018 homes, and deliveries increased 4% to 23,034 units.
The company ended the quarter with a backlog of 13,936 homes valued at approximately $5.2 billion. But here's the kicker: Lennar guided for lower average selling prices and softer deliveries in the first quarter of fiscal 2026. Management cited affordability pressures and weak consumer confidence as the culprits—basically, potential homebuyers are feeling stretched and hesitant.
The housing market remains caught between elevated mortgage rates and stubbornly high home prices, making it tough for builders to maintain momentum even when demand exists.
Tesla: Record Highs as Autonomy and Robotics Excitement Builds
Tesla Inc. (TSLA) climbed 3.07% to close at $489.88, reaching an intraday high of $491.50 and a low of $465.83. That intraday peak represents a fresh 52-week high—and an all-time record for the stock—putting shares dramatically above the 52-week low of $214.25.
The electric vehicle and AI-focused company extended its breakout as enthusiasm around autonomy, robotics, and software intensified. There's been a recent surge in interest around Tesla's robotaxi program and its Optimus humanoid robots, which represent potential new revenue streams beyond selling cars. Wedbush analyst Dan Ives added to the bullish narrative with commentary suggesting that 2026 could be a "monster year" for what he described as an automaker-turned-technology powerhouse.
Tesla's valuation increasingly reflects investors betting on its future as a full-stack AI and robotics company rather than just a car manufacturer. Whether those bets pay off remains to be seen, but for now, the market is clearly willing to price in significant upside from those next-generation businesses.
Tuesday's trading session highlighted how quickly sentiment can shift based on regulatory developments, forward guidance, and strategic pivots. From cannabis policy to housing affordability to AI ambitions, these five stocks captured the diverse forces shaping investor attention right now.
